Next-generation active immunization approach for synucleinopathies: Implications for Parkinson's disease clinical trials

Acta Neuropathologica

Volumn 127, Issue 6, 2014, Pages 861-879

  Mandler, Markus ^a   Valera, Elvira ^b   Rockenstein, Edward ^b   Weninger, Harald ^a   Patrick, Christina ^b   Adame, Anthony ^b   Santic, Radmila ^a   Meindl, Stefanie ^a   Vigl, Benjamin ^a   Smrzka, Oskar ^a   Schneeberger, Achim ^a   Mattner, Frank ^a   Masliah, Eliezer ^b  

^a AFFiRiS GmbH   (Austria)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AFFITOME ; AFFITOPE ; Alpha synuclein; Immunotherapy; Parkinson's disease; Vaccination

Indexed keywords

AFFITOPE; AFFITOPE 1; ALPHA SYNUCLEIN; OLIGOMER; PEPTIDE VACCINE; UNCLASSIFIED DRUG; ANTIBODY; SNCA PROTEIN, HUMAN; SNCA PROTEIN, MOUSE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD PROTEIN DISORDER; CEREBROSPINAL FLUID; CYTOKINE PRODUCTION; DIFFUSE LEWY BODY DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; IN VIVO STUDY; MOUSE; NERVE FIBER; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPSE; SYNUCLEINOPATHY; T LYMPHOCYTE; VACCINATION; ANIMAL; AXON; BLOOD; C57BL MOUSE; CAUDATE NUCLEUS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENETICS; HUMAN; LEWY BODY DISEASE; MEMORY DISORDERS; METABOLISM; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PUTAMEN; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES; AXONS; CAUDATE NUCLEUS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; LEWY BODY DISEASE; MEMORY DISORDERS; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; PARKINSON DISEASE; PUTAMEN; SYNAPSES; T-LYMPHOCYTES; VACCINATION;

EID: 84901682081     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1256-4     Document Type: Article

References (83)

1. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154-169. doi:10.1111/j.1365-2567. 2009.03225.x
2. Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Romer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B (2013) Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model. BMC Neurosci 14:6. doi:10.1186/1471-2202-14-6
3. Angot E, Brundin P (2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 3):S143-S147. doi:10.1016/S1353-8020(09) 70802-8
4. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR (2008) Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 33(12):2416-2426. doi:10.1007/s11064-008-9697-6
5. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115-9129. doi:10.1523/JNEUROSCI.2361-07.2007 (Pubitemid 47312068)
6. Bach P, Tschäpe JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, Müller UC (2009) Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 182(12):7613-7624. doi:10.4049/jimmunol.0803366
7. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ (2012) Antibody-aided clearance of extracellular á-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32(39):13454-13469. doi:10.1523/JNEUROSCI.1292-12.2012
8. Bajetto A, Bonavia R, Barbero S, Piccioli P, Costa A, Florio T, Schettini G (1999) Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cellderived factor 1. J Neurochem 73(6):2348-2357
9. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640-644. doi:10.1038/385640a0
10. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917-924. doi:10.1038/nn1715 (Pubitemid 43980506)
11. Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics: J Am Soc Exp Neurotherap 9(2):297-314. doi:10.1007/ s13311-012-0104-2
12. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571-576 (Pubitemid 30070350)
13. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O (2010) Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285(14):10563-10571. doi:10.1074/jbc.M109.035477
14. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5(2):e9313. doi:10.1371/journal.pone.0009313
15. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27(34):9220-9232. doi:10.1523/JNEURO SCI.2617-07.2007
16. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4):685-697. doi:10.1016/j.neuron.2011.11.033
17. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106(31):13010-13015. doi:10.1073/pnas.0903691106
18. Eizenberg O, Faber-Elman A, Lotan M, Schwartz M (1995) Interleukin- 2 transcripts in human and rodent brains: possible expression by astrocytes. J Neurochem 64(5):1928-1936
19. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alphasynuclein. J Neurosci 24(42):9434-9440. doi:10.1523/JNEURO SCI.3080-04.2004
20. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47. doi:10.1186/1750-1326-4-47
21. Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E (2013) Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am J Pathol 182(3):940-953. doi:10.1016/j.ajpath.2012.11.018
22. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O (2012) alpha-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47(2):258-267. doi:10.1016/j.nbd.2012.04.009
23. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95(18):10896-10901 (Pubitemid 28413165)
24. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10(4):717-721 (Pubitemid 29393812)
25. Hashimoto M, Masliah E (1999) Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 9(4):707-720 (Pubitemid 29470963)
26. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37(4):314-327
27. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467-475
28. Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 148(5):1517-1529 (Pubitemid 26135893)
29. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287(23):19440-19451. doi:10.1074/jbc. M112.346072
30. Kohler G, Milstein C (1976) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6(7):511-519. doi:10.1002/eji.1830060713
31. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alphasynuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27(6):1405-1410. doi:10.1523/JNEUROSCI.4564-06.2007
32. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312-318
33. Lalonde R, Qian S (2007) Exploratory activity, motor coordination, and spatial learning in Mchr1 knockout mice. Behav Brain Res 178(2):293-304. doi:10.1016/j.bbr.2007.01.006 (Pubitemid 46350787)
34. Lalonde R, Strazielle C (2009) Exploratory activity and motor coordination in old versus middle-aged C57BL/6J mice. Arch Gerontol Geriatr 49(1):39-42. doi:10.1016/j.archger.2008.04.009
35. Lansbury PT Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 96(7):3342-3344
36. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38-48. doi:10.1038/nrn3406
37. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322(5):1089-1102 (Pubitemid 35266514)
38. Lee HJ, Suk JE, Bae EJ, Lee SJ (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372(3):423-428. doi:10.1016/j.bbrc.2008.05.045
39. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285(12):9262-9272. doi:10.1074/jbc.M109.081125
40. Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70(4):339-348. doi:10.1016/j.neures.2011.05.008
41. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7(2):e31302. doi:10.1371/journal.pone.0031302
42. Luthi-Carter R (2003) Progress towards a vaccine for Huntington's disease. Mol Ther 7(5 Pt 1):569-570
43. Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E (2012) Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AßPP transgenic mice using a novel monoclonal antibody. J Alzheimers Dis 28(4):783-794. doi:10.3233/JAD-2011-111208
44. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6):857-868. doi:10.1016/j.neuron.2005.05.010 (Pubitemid 40805347)
45. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338. doi:10.1371/journal.pone.0019338
46. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265-1269 (Pubitemid 30112148)
47. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98(21):12245-12250. doi:10.1073/pnas.211412398 (Pubitemid 32959858)
48. McKeith IG (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18(4):865-902
49. Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA (2011) Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des 17(5):508-520
50. Metz GA, Schwab ME (2004) Behavioral characterization in a comprehensive mouse test battery reveals motor and sensory impairments in growth-associated protein-43 null mutant mice. Neuroscience 129(3):563-574. doi:10.1016/j. neuroscience.2004.07.053 (Pubitemid 39487110)
51. Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572-579 (Pubitemid 36626236)
52. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408(6815):982-985. doi:10.1038/35050116 (Pubitemid 32101645)
53. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214-3220 (Pubitemid 30263139)
54. Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M (1998) Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 429(2):167-172 (Pubitemid 28288203)
55. Okuno T, Nakatsuji Y, Kumanogoh A, Moriya M, Ichinose H, Sumi H, Fujimura H, Kikutani H, Sakoda S (2005) Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. J Neurosci Res 81(6):874-882. doi:10.1002/jnr.20599 (Pubitemid 41532153)
56. Olanow CW, Prusiner SB (2009) Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 106(31):12571-12572. doi:10.1073/pnas.0906759106
57. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D (1997) Neurotactin, a mem-brane- anchored chemokine upregulated in brain inflammation. Nature 387(6633):611-617. doi:10.1038/42491 (Pubitemid 27248766)
58. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282(8):5862-5870. doi:10.1074/jbc.M608126200 (Pubitemid 47093740)
59. Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31(5):711-721. doi:10.1016/j.immuni.2009.09.010
60. Rockenstein E, Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59(11):1093-1102. doi:10.1016/j.addr.2007.08.013 (Pubitemid 47615209)
61. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568-578. doi:10.1002/jnr.10231 (Pubitemid 34575622)
62. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2013) Incidence and pathology of synucleinopathies and tauopathies related to Parkinsonism. JAMA Neurol :1-7. doi:10.1001/ja maneurol.2013.114
63. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173-177. doi:10.1038/22124 (Pubitemid 29327547)
64. Schneeberger A, Mandler M, Mattner F, Schmidt W (2010) AFFITOME® technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 6(11):948-952
65. Schneeberger A, Mandler M, Mattner F, Schmidt W (2012) Vaccination for Parkinson's disease. Parkinsonism Relat Disord 18(Suppl 1):S11-S13. doi:10.1016/S1353-8020(11)70006-2
66. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30(24):8083- 8095. doi:10.1523/JNEUROSCI.1091-10. 2010
67. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T (2002) Immunization delays the onset of prion disease in mice. Am J Pathol 161(1):13-17. doi:10.1016/S0002-9440(10)64151-X
68. Singh VK, Mehrotra S, Agarwal SS (1999) The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20(2):147-161
69. Solomon B (2007) Active immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine 25(16):3053-3056. doi:10.1016/j.vaccine.2007.01.069
70. Sonobe Y, Yawata I, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A (2005) Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res 1040(1-2):202-207. doi:10.1016/j.brainres.2005. 01.100 (Pubitemid 40459635)
71. Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E (2012) Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. Mol Therapy: J Am Soc Gene Therapy. doi:10.1038/mt.2012.66
72. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29(43):13578-13588. doi:10.1523/JNEUROSCI.4390-09.2009
73. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1(1):14. doi:10.1186/1742-2094-1-14
74. Trojanowski JQ, Lee VM (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55(2):151-152 (Pubitemid 28110056)
75. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4):397-405
76. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 274(7):1862-1877. doi:10.1111/j.1742-4658.2007.05733.x (Pubitemid 46426920)
77. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α- synucleinopathy. Exp Neurol 234(2):405-416. doi:10.1016/j.expneurol.2012.01.008
78. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 30(18):6236-6246. doi:10.1523/JNEURO SCI.0567-10.2010
79. Valera E, Masliah E (2013) Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther. doi:10.1016/j.pharmthera. 2013.01.013
80. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20(16):6021-6029 (Pubitemid 30658395)
81. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35(43):13709-13715. doi:10.1021/bi961799n (Pubitemid 26363912)
82. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15(4):555-569
83. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108(10):4194-4199. doi:10.1073/pnas.1100976108